Estrella Immunopharma (NASDAQ:ESLA) Posts Quarterly Earnings Results

Estrella Immunopharma (NASDAQ:ESLA) issued its earnings results on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, FiscalAI reports.

Estrella Immunopharma Stock Performance

Shares of ESLA traded down $0.02 during mid-day trading on Thursday, hitting $0.72. 16,211 shares of the stock were exchanged, compared to its average volume of 110,108. The company has a market cap of $31.18 million, a PE ratio of -2.13 and a beta of 0.88. Estrella Immunopharma has a 52-week low of $0.68 and a 52-week high of $3.15. The firm has a 50-day moving average of $0.89 and a two-hundred day moving average of $1.14.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Estrella Immunopharma from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $8.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of ESLA. BlackRock Inc. bought a new stake in Estrella Immunopharma in the second quarter worth $54,000. XTX Topco Ltd increased its holdings in shares of Estrella Immunopharma by 376.9% in the 4th quarter. XTX Topco Ltd now owns 49,472 shares of the company’s stock worth $77,000 after buying an additional 39,099 shares during the last quarter. Quadrature Capital Ltd purchased a new stake in shares of Estrella Immunopharma during the 4th quarter valued at about $43,000. Marshall Wace LLP bought a new position in shares of Estrella Immunopharma in the 4th quarter valued at about $88,000. Finally, State Street Corp grew its position in Estrella Immunopharma by 93.5% in the fourth quarter. State Street Corp now owns 43,252 shares of the company’s stock worth $67,000 after acquiring an additional 20,900 shares in the last quarter. 0.35% of the stock is owned by hedge funds and other institutional investors.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103.